ArticleFrontiers in oncology2025
Cerebral CIC-NUTM1 rearrangement sarcoma- case report and review of the literature.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dural CIC::DUX4 sarcoma presenting with intracranial hemorrhage at both initial diagnosis and recurrence: a case report and literature review.Brain tumor pathology · 2026Article
- Undifferentiated round cell sarcoma with CIC::NUTM1 fusion: expanding the clinicopathologic spectrum of a rare molecular variant of CIC-rearranged sarcoma.Virchows Archiv : an international journal of pathology · 2026Article
- Deep learning for scene understanding in mitochondrial dysregulation and blood cancer diagnosis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ewing sarcoma and Ewing-like sarcoma are both highly aggressive small round cell sarcomas, while CIC rearranged sarcoma (CRS), the most common specific type of Ewing-like sarcoma, exhibits a more aggressive course than Ewing sarcoma and represents a distinct family of sarcomas. NUT midline carcinoma family member 1 (NUTM1) is a characteristic fusion gene of NUT midline carcinoma. In this paper, the intracranial tumor CIC is mainly fused with NUTM1, which is considered to be a molecular variant of CIC sarcoma. Case presentation: We report a 9 years old female patient diagnosed with CIC rearrangement sarcoma with CIC-NUTM1 gene rearrangement and PMS2 frameshift mutation, WHO grade 4. We treated the patient with surgical resection. Due to the poor postoperative condition of the patient, coupled with the inherently poor prognosis of CIC-NUTM1 sarcoma, the patient ultimately had a short survival time and the treatment outcome was not satisfactory. Conclusion: We experienced a rare case of an intracranial tumor with CIC-NUTM1 fusion and a PMS2 frameshift mutation. Due to the small sample size, rapid progression, and poor prognosis associated with this type of tumor, it is essential to enhance understanding and diagnosis of this type of sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.